EICHOR
● Recruiting
An Evaluation of Dose-escalation for Intrathoracic Tumours
Condition: Lung Cancers · Sponsor: Chris Goodman
About this study
This is a pragmatic trial with patients randomized between standard of care palliative thoracic radiation therapy (RT) vs. hypofractionated, dose-escalated, esophageal-sparing (HD-ES) intensity modulated radiation therapy (IMRT). The investigators hypothesize that the use of advanced radiation planning techniques to optimize dose to esophagus will permit the safe delivery of a modestly dose-escalated five-fraction course of palliative radiation to intrathoracic malignancies. This approach aims to deliver higher biologically effective doses while improving toxicity when compared to conventional approaches with the goal of prolonging high-quality overall survival.
This description comes directly from the study's public registry record.
Talk to the study team
Christopher Goodman, MD · 519-685-8650 · Chris.Goodman@lhsc.on.ca
David Palma, MD · 519-685-8650 · David.Palma@lhsc.on.ca
Always discuss trial participation with your own doctor first.
Locations (3)
| British Columbia Cancer Agency Center for the Southern Interior | Kelowna, British Columbia, Canada | Recruiting |
| London Health Sciences Center Research Institute (Formerly Lawson Research Institute) | London, Ontario, Canada | Recruiting |
| Waterloo Regional Health Network | Waterloo, Ontario, Canada | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06794125